
Opinion|Videos|May 28, 2025
Screening and Managing Comorbidities for Patients With Duchenne Muscular Dystrophy
Author(s)Diana Castro, MD
Explore the comprehensive comorbidities of Duchenne Muscular Dystrophy, including cognitive, respiratory, and nutritional challenges faced by patients.
Advertisement
Episodes in this series

Summary for Physicians
Common Comorbidities in Duchenne Muscular Dystrophy (DMD)
Patients with DMD patients often experience a wide range of comorbidities that require ongoing monitoring and management. These include the following:
- Cognitive and Behavioral Issues
- Affects around 1/3 of patients, presenting as autism, attention-deficit/hyperactivity disorder, learning difficulties, and behavioral challenges.
- Ophthalmologic Concerns
- Annual ophthalmology checkups are recommended due to the risk of cataracts from steroid use.
- Swallowing and Respiratory Issues
- Difficulty in swallowing develops later, but respiratory muscle weakness (diaphragm and intercostal muscles) can cause restrictive lung disease and obstructive sleep apnea.
- Cardiac Issues
- Cardiomyopathy can be detected early, with studies showing changes in cardiac MRI at 10 years old or younger in 17% of patients.
- Gastrointestinal and Urinary Complications
- Common issues include reflux, constipation, urinary urgency, and retention, with kidney stones also a concern in adults due to low water intake.
- Orthopedic Problems
- Patients often develop contractures (ankles, knees, hips, elbows, hands) and scoliosis, though the latter is less common due to steroid use. Some patients may still develop scoliosis in adulthood, requiring surgery.
- Psychological Problems
- Depression, anxiety, and obsessive-compulsive disorder behaviors are common in this population.
Comorbidity Screening Approach
A multidisciplinary approach is crucial for effective care, focusing on early detection and management:
- Neurological Screening
- As a neurologist, I screen for motor and cognitive issues and make referrals to specialists when needed (e.g.eg, gastroenterologists, endocrinologists).
- Cardiological Monitoring
- Regular electrocardiograms, echocardiograms, and cardiac MRIs are essential. Early intervention with medications can prevent cardiac deterioration.
- Pulmonary Function Testing
- Pulmonologists and respiratory therapists perform pulmonary function tests, which are most reliable after 5 years of age.
- Nutrition Support
- Nutritionists monitor and manage obesity (a significant issue due to steroids) by promoting a low-carb, low-fat, low-sugar diet and providing vitamin D and B12 supplements. Regular lab work includes lipid profiles and vitamin testing.
- Physical and Occupational Therapy
- Standardized tests, such as North Star and 10-meter walk/run, help track motor function and progression, guiding equipment needs.
Advertisement
Related to this article

The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.

A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral hemorrhage reduced recurrent stroke risk.

A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.

Fast Track status covers AV-1959R, an investigational amyloid-beta vaccine, for preventing Alzheimer disease in cognitively unimpaired adults with amyloid pathology.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Clene Submits NDA Seeking Accelerated Approval for ALS Drug
2
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
3
CALLIPER Extension Data Show Sustained Disability Outcomes With Vidofludimus Calcium in Progressive MS
4
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
5



